North China Pharmaceutical Group Corporation ( NCPC)

Welcome to

Free Member

North China Pharmaceutical Group Corporation ( NCPC)
Indonesia

Home
Company Info
Contact Us
Share your thoughts
Language
- English

Company Profile

Company Contact

Name:

Mr. Sandy Boy

E-mail:

Send Message

Mobile Number:

Phone Number:

Address:

Jakarta, Jakarta
Indonesia

Average User Review

There is no review for this company - Write a review

Registration Date:

Nov. 3, 2015

Last Updated:

Nov. 29, 2015

Business Nature:

Manufacturing of Health & Beauty category

Want to contact this company?

Add to Basket or Send Message

Your inquiry will be recorded in "Member Trade Mail".

Put on Company Partner

Recommend to your friends

Company Brief

North China Pharmaceutical Group Corp. ( NCPC) is a leading pharmaceutical manufacturer in China. NCPC, in its early days, was one of the key construction projects during Chinese First Five-Year Plan. After fiver years of construction from the foundation date in June 1953, the successful operation started in June 1958. Being one of the world leading antibiotic producers both in technology and production with 50 years development, pharmaceutical industry in key economic indexes, ranking one of the Top 500 Enterprises and the best profit-makers in China.

Products:
NCPCâ € ™ s main businesses covers: over 590 varieties, ranging from antibiotic bulks and formulations, vitamins and nutrition products, biotech products, immunosuppressant, and pesticide to veterinary drugs; the annual sales volume for antibiotic bulks is up to 8, 000 tons, for vitamins is 23, 000 tons, for antibiotic intermediates is up to 5, 000 tons, and for formulations amounts to 4.1 billion vials/ tablets/ capsules; and the main products now occupies a considerably big share of the domestic market. The output and sales volume of Penicillin, Amoxicillin, and Streptomycin sulfate, Cefradine, 7-ADCA, Vitamin C and Vitamin B12 are ranking in the forefront of the world.

I am familiar with this company and want to review it.

You have [3] new inquiries.